Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SFM +17.4%, HLIT +15.7%, FFIV +13.7%, VRNS +10.6%, DAWN +9.5%, TLRY +8.7%, NMR +7.2%, HWM +7.1%, BYON +7%, PYPL +5.9%, PLOW +5.7%, SWK +5.6%, CORT +5.3%, NEOG +5.3%, LDOS +5.2%, ZBRA +4.6%, CDP +4.4%, JBLU +4.2%, PJT +3%, PSX +2.6%, SPGI +2.5%, AMT +2.4%, HAYW +1.9%, CNP +1.7%, STNG +1.6%, SOFI +1.5%, INCY +1.5%, NEO +1.4%, IT +1.4%, ST +1.3%, BP +1.3%, WELL +1.1%, PFE +1%, XYL +1%, AUDC +0.9%
Other news:
- GUTS +10.8% (FDA breakthrough device designation for revita in weight maintenance for people with obesity who discontinue GLP-1 based drugs)
- DRVN +5.7% (Closes $275 Million Securitization Issuance to Refinance Existing Debt)
- FEIM +4.2% (to delay 10-K filing)
- VSTO +3.9% (announces that its Board of Directors has commenced a review of strategic alternatives)
- VSTM +3.6% (FDA orphan drug designation for avutometinib and defactinib)
- NVO +2.7% (Older GLP-1 drugs might help protect brains of patients with early Alzheimer's disease, according to Stat News)
- ALGM +2.1% (repurchases shares held by Sanken Electric)
- BNTX +1.6% (topline data from the ongoing Phase 2 clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment)
- NTLA +1.5% (authorization of its Clinical Trial Application by the United Kingdom's Medicine and Healthcare products Regulatory Agency to initiate a Phase 1/2 study evaluating NTLA-3001)
- SD +1.2% (to acquire assets in Western Anadarko basin for $144 mln)
- AMRX +1.2% (FDA approval for potassium phosphates injection IV Bags)
Analyst comments:
- AFRM +4.9% (upgraded to Buy from Neutral at BofA Securities)
- ASML +2.5% (upgraded to Overweight from Equal Weight at Barclays)
- BV +1.9% (upgraded to Outperform from Neutral at Robert Baird)
- COLL +1.5% (upgraded to Buy from Neutral at H.C. Wainwright)